It’s not far off crunch time for Roche’s potential spinal muscular atrophy (SMA) drug, risdiplam, which the big Swiss pharma hopes will generate blockbuster revenues as well as taking marke
As the US opioid addiction crisis continues, it seems the FDA is less than convinced about the new painkilling drugs that the pharma industry is developing.
